fallond

Declan Fallon

I have been an active investor for over 10 years, providing daily market commentary on my personal blog, and more recently providing analysis on equities for the Fool. Zoologist, with a Ph.D. in Nematology, but a resulting career in Finance. Digging for gold in Data!

fallond’s Activity

Tue Apr 1

NL

Article

fallond published an article 12:29 PM

The Battle of the Cruise Liners

A beaten-up sector has found it hard to garner positive publicity, but should you be using this as an opportunity to buy value?

Wed Mar 26

NL

Article

fallond published an article 5:06 PM

Does This Stock Warrant a $9 Billion Market Cap?

Incyte Pharmaceuticals has jumped 170% over the past year, but while it enjoys good growth in its one and only drug, Jakafi, investors are looking for more.

Mon Dec 9

NL

Article

fallond published an article 11:43 AM

Treating Parkinson's Disease Psychosis

ACADIA Pharmaceuticals is the only company developing a drug to treat psychosis associated with Parkinson's disease, a symptom that affects 60% of sufferers and indirectly impacts caregivers and victims' families.

Fri Nov 22

NL

Article

fallond published an article 4:05 PM

Opportunities in Lung Cancer Therapies

The market for lung cancer therapies is expected to reach $7 billion in 2019, but the successful treatment of lung cancer involves a complex relationship of genetic relationships. What companies are leading the charge to decode these relationships?

Fri Nov 8

NL

Article

fallond published an article 10:34 AM

Is This Cubist's Biggest Opportunity?

The war on microbes has an important ally. Cubist Pharmaceuticals (Nasdaq: CBST) has a $1 billion antibiotic franchise and is getting ready to launch another. It also has partnerships with big pharmas AstraZeneca (NYSE: AZN) and Novartis (NYSE: NVS).

Tue Oct 15

NL

Article

fallond published an article 1:37 PM

The Fight for the Hypercholesterolemia Market

Three companies are fighting it out for the homozygous familial hypercholesterolemia market, while one is aiming at the heterozygous familial hypercholesterolemia. As a rare disease, the payoff can be high, so who will win the race for the largest [more]

Mon Oct 7

NL

Article

fallond published an article 2:41 PM

Array BioPharma Needs a Partner to Take It to the Next Level

Array BioPharma is aiming to break in to the highly lucrative asthma market with its development treatment, ARRY-502. The only problem is it hasn't secured a partner to help develop the treatment into a commercial drug.

Fri Sep 27

NL

Article

fallond published an article 11:45 AM

A Reshuffle in a $27 Billion Market

GlaxoSmithKline's Advair controls the largest portion of the asthma and COPD market, but it will soon find itself facing competition from another products, including one from its own stable. How will things shape out for this $27 billion market in [more]

Tue Sep 17

NL

Article

fallond published an article 10:24 AM

Investing in Counteracting Biological and Chemical Agents

Biological and chemical agents are a lethal scourge of war, but Emergent Biosciences is developing countermeasures to a wide range of such agents.

Thu Sep 12

NL

Article

fallond published an article 12:05 PM

The Neulasta Question

Amgen will lose its patent for Neulasta in 2015, opening up the $4 billion in sales revenue to a rival generic. As the second-highest-earning drug for Amgen, will the company be able to make up the inevitable losses a generic rival will bring?

Wed Sep 11

NL

Article

fallond published an article 4:18 PM

Next Leaders in Technology and Health Care

Health care and technology stocks are leading the earnings parade. Read about three stocks to lead the charge.

Mon Sep 2

NL

Article

fallond published an article 12:46 PM

The Treatment of Rare Diseases Offers Unique Opportunities

A company generating more than $1 billion in sales from treating diseases with a prevalence of just a few thousand Americans? Yes - it's possible, and $1 billion may just be the start of it.

Thu Aug 29

NL

Article

fallond published an article 11:27 AM

How to Build Wealth From Farming

Slow economies are often a boon to the farming industry. Fertilizer manufacturers are well placed to take advantage, but they are not the only stocks to benefit.

Mon Aug 26

NL

Article

fallond published an article 1:44 PM

Tackling Pain and Addiction

Alkermes offers more than schizophrenia and MS treatments: Its research into addiction and pain management could be a more important source of revenue in the years ahead.

CAPS Stats & Trivia

CAPS Player Rating < 20
Player Rank 0 out of 75065
Score 0.00
Score Change Today -4.96
Accuracy 0.00%
Active Picks 1
Total Picks 16
Best Pick OMPI (+64.21)
Worst Pick NTES (-26.87)
Average Score per Pick 2.85
Charms Earned 0
Highest Rated Favorite EverydayInvestor
Go to fallond’s CAPS page

Boards Stats & Trivia

Board Posts 1
Recs Received 0
People who have rec'd these posts 0
Recs to Posts Ratio (last 30 days) N/A
Threads Started 1
Threads Started Percentage 100.00 %
Most Frequent Board Folly in Hawaii
Very First Post DYII anyone (5/8/2001)
Percentage of Posts Rec'd 0.00 %
Show fallond’s 10 Latest Posts